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To improve the efficacy of chemoradiation therapy for locally advanced pancreatic cancer and begin to establish
patient selection criteria, we investigated the combination of the WEE1 inhibitor AZD1775 with gemcitabine-
radiation in homologous recombination (HR) repair proficient and deficient pancreatic cancers. Sensitization to
gemcitabine-radiation by AZD1775 was assessed in pancreatic cancer cells by clonogenic survival and in patient-
derived xenografts by tumor growth. The contributions of HR repair inhibition and G2 checkpoint abrogation to
sensitization were assessed by γH2AX, BRCA2 manipulation, and RAD51 focus formation and pHistone H3 flow
cytometry, respectively. We found that AZD1775 sensitized to gemcitabine-radiation in BRCA2 wild-type but not
BRCA2 mutant pancreatic cancer cells. In all cells, AZD1775 caused inhibition of CDK1 phosphorylation and G2
checkpoint abrogation. However, sensitization by AZD1775 was associated with persistent γH2AX and inhibition
of RAD51 focus formation. In HR-proficient (BRCA2 wild-type) or -deficient (BRAC2 null) isogenic cells, AZD1775
sensitized to gemcitabine-radiation in BRCA2 wild-type, but not in BRCA2 null cells, despite significant G2
checkpoint abrogation. In patient-derived pancreatic tumor xenografts, AZD1775 significantly inhibited tumor
growth and impaired RAD51 focus formation in response to gemcitabine-radiation. In conclusion, WEE1 inhibition
by AZD1775 is an effective strategy for sensitizing pancreatic cancers to gemcitabine chemoradiation. Although
this sensitization is accompanied by inhibition of CDK1 phosphorylation and G2 checkpoint abrogation, this
mechanism is not sufficient for sensitization. Our findings demonstrate that sensitization to chemoradiation by
WEE1 inhibition results from inhibition of HR repair and suggest that patient tumors without underlying HR defects
would benefit most from this therapy.
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Radiation in combination with concurrent gemcitabine or 5-fluorouracil
is the standard of care for locally advanced pancreatic cancer. In
combination with gemcitabine, radiation significantly improves survival
compared with gemcitabine treatment alone [1]. Furthermore, recent
studies from our group and others suggest that intensification of highly
conformal radiation may extend survival in locally advanced patients
beyond the approximate 1-year survival associated with standard
chemoradiation therapies [2,3]. Although recent advancements in
systemic therapy for pancreatic cancer, such as FOLFIRINOX and
nab-paclitaxel with gemcitabine, have improved survival in metastatic
pancreatic cancer [4,5], these therapies have not yet been effectively
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approximately 30% of pancreatic cancer patients die from local disease
progression [6] and radiation is the only therapy which provides local
tumor control in surgically unresectable patients, strategies for improving
both local and systemic disease therapy are critical for improving overall
survival in pancreatic cancer patients.
One promising strategy for improving both local and systemic
disease control is by selective exploitation of DNA damage response
pathways in cancer cells [7]. In response to DNA damage, cells
activate both cell cycle checkpoint and DNA repair pathways which
function cooperatively to prevent the propagation of cells with
damaged DNA [8]. The WEE1 kinase is an important regulator of
the cellular response to DNA damage, as it catalyzes phosphorylation
of CDK1, resulting in CDK1 inhibition and arrest of cells in the G2
phase of the cell cycle [9]. WEE1 also negatively regulates
CDK1-dependent replication origin firing and thus acts to prevent
aberrant origin firing leading to nucleotide pool depletion and
replication stress [10]. In addition, we and others have shown that
WEE1 regulates homologous recombination (HR) repair, although
the mechanisms have not been fully elucidated [11,12].
Given the critical role of WEE1 in regulating the cellular response to
DNA damage,WEE1 is a promising target for cancer therapy [13]. The
small-molecule WEE1 inhibitor AZD1775 is a first-in-class agent that
has shown anticancer activity both alone and in combination with
radiation and chemotherapy in preclinical studies [14–17]. Many
clinical trials (phase 1 and 2) are under way combining AZD1775 with
radiation, chemotherapy, and chemoradiation for several disease sites
including cancers of the head and neck, lung, ovary, cervix, and pancreas
as well as diffuse intrinsic pontine glioma and glioblastoma. As a single
agent, AZD1775 exhibits cytotoxicity across various cancer cell types
with mechanisms that have been attributed to regulation of both
initiation and progression of DNA replication, DNA damage during
DNA replication, as well as unscheduled mitotic entry [10,14,18,19].
AZD1775 is also efficacious in combination with radiation [15,20–22]
or chemotherapies such as gemcitabine, 5-fluorouracil, cytarabine,
temozolomide, and cisplatin [16,23–27]. The vast majority of these
studies demonstrating sensitization to radiation or chemotherapy by
AZD1775 have implicated abrogation of the G2 checkpoint and/or
unscheduled mitotic entry as the mechanism. Recently, however, it
was suggested that regulation of DNA double-strand break (DSB)
repair by WEE1 inhibition may be a mechanism of radiosensitization
[21]. Consistent with this, our prior study indicated that inhibition of
HR repair by AZD1775 is also a possible mechanism for radio-
sensitization [11].
To determine the efficacy of WEE1 inhibitors in combination with
chemoradiation in pancreatic cancer and to begin to identify
mechanisms that might inform patient selection, in this study, we
investigated AZD1775 as a sensitizer to gemcitabine-based chemo-
radiation in HR-proficient (BRCA2 wild-type) and HR-deficient
(BRCA2 mutant) pancreatic cancers. When we found that
sensitization to chemoradiation by AZD1775 occurred in BRCA2
wild-type (MiaPaCa-2, Panc-1) but not BRCA2 mutant (Capan-1)
pancreatic cancer cells, we went on to hypothesize that inhibition of
HR repair byWEE1 inhibition is a critical mechanism of sensitization
by AZD1775. To test this hypothesis, we assessed sensitization to
chemoradiation by AZD1775 in BRCA2 isogenic cell lines. In
addition, we tested the ability of AZD1775 to sensitize and inhibit
HR repair in vivo in patient-derived pancreatic tumor xenografts.
The findings of this study provide a preclinical rationale for thedevelopment of AZD1775 as a sensitizer to gemcitabine-radiation in
selected HR-proficient locally advanced pancreatic cancers.
Materials and Methods
Cell Culture and Drug Solutions
MiaPaCa-2 and Panc-1 cells were obtained from and authenticated
(via short tandem repeat profiling) by the American Type Culture
Collection (2009 and 2006, respectively). Cells were cryopreserved
within 6 months of authentication. Capan-1.NEO is a clonal cell line
expressing the neomycin resistance gene obtained from S. Powell
(Memorial Sloan Kettering Cancer Center, New York, NY) [28].
Cells were grown in Dulbecco’s modified Eagle’s medium (DMEM)
(MiaPaCa-2), RPMI 1640 (Panc-1), or Iscove's modified Dulbecco's
medium (Capan-1) supplemented with 10% fetal bovine serum (Life
Technologies), 2 mM L-Glutamine (Sigma), penicillin, and
streptomycin (Sigma). Isogenic DLD1 cells were obtained from
Horizon Discovery (2014) and grown in DMEM or McCoy’s as
described above except that DLD1 BRCA2 null cells were maintained
under selection in 0.1 mg/ml of hygromycin (Invitrogen). For in vitro
experiments, AZD1775 (AstraZeneca) was dissolved in dimethyl
sulfoxide (Sigma) and stored in aliquots at −20°C. For in vivo
experiments, AZD1775 was suspended in 0.5% methylcellulose
(Sigma) and stored for a maximum of 5 days at room temperature
with constant stirring. Gemcitabine (Eli Lily) was dissolved in either
PBS or saline for in vitro or in vivo use, respectively.
Clonogenic Survival Assays
Cells treated with drugs or radiation were processed for clonogenic
survival as previously described [29,30]. Radiation survival curves
were normalized for drug toxicity, and the radiation enhancement
ratio was calculated as the ratio of the mean inactivation dose (area
under the cell survival curve) under control conditions divided by the
mean inactivation dose after drug exposure [31]. A value significantly
greater than 1 indicates radiosensitization. Cytotoxicity in the absence
of radiation treatment was calculated by normalizing the plating
efficiencies of drug-treated cells to non–drug-treated cells.
Flow Cytometry
Cells were trypsinized, washed with ice-cold PBS, and fixed at a
concentration of 2 × 106 cells/ml in ice-cold 70% ethanol. For pHistone
H3 analysis, cells were incubated with a rabbit anti-pHistone H3 (S10)
antibody (Millipore) as previously described [32]. For γH2AX analysis,
samples were incubated with a mouse anti–γH2AX-specific antibody
(clone JBW301; Millipore) overnight at 4°C followed by incubation
with a fluorescein isothiocyanate–conjugated secondary antibody
(Sigma) as previously described [33]. For quantification of γH2AX
positivity, a gate was arbitrarily set on the control, untreated sample to
define a region of positive staining for γH2AX of approximately 5%.
This gate was then overlaid on the treated samples. Samples for both
analyses were stained with propidium iodide to measure total DNA
content and analyzed on a FACScan flow cytometer (BectonDickinson)
with FlowJo software (Tree Star).
Immunoblotting
Whole cell lysates were prepared in cold SDS lysis buffer (10 mM
Tris pH 7.4, 2% SDS) supplemented with PhosSTOP phosphatase
inhibitor and Complete protease inhibitor tablets (Roche) as previously
described [29]. The following antibodies were used: CDK1, pCDK1
(Y15), CHK1, pCHK1 (S345), GAPDH (Cell Signaling Technology),
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software (NIH).
Immunofluorescence
For in vitro immunofluorescence experiments, cells were grown and
treated on cover slips in 12-well dishes. Following treatment, cells were
fixed and stained as previously described [34] with a mouse monoclonal
RAD51 antibody (GeneTex) and 4′,6-diamidino-2-phenylindole
(DAPI). For in vivo immunofluorescence experiments, RAD51 foci
in tumor xenografts were assessed based on a previously published
protocol [35] with the following modifications. Cryosections were fixed
with 4% para-formaldehyde in PBS for 5minutes at room temperature.
After permeabilization in ice-cold methanol for 5 minutes, slides were
washed with PBS and blocked with 5% goat serum for 1 hour at room
temp. Samples were probed with anti-RAD51 primary antibody
(1:300, Calbiochem) in 3% goat serum/PBS for 1 hour in a humidified
chamber. Slides were washed with PBS and stained with Alexafluor-488
secondary antibody (1:1000 in 3% goat serum/PBS; EMD Millipore)
for 1 hour. After washing with PBS, samples were stained with 1 mg/ml
of DAPI and mounted with Prolong Gold antifade mounting medium.
Samples were imaged with an Olympus IX71 FluoView confocal
microscope (Olympus America) with a 60× oil objective. Fields were
chosen at random based on DAPI staining. For quantitation of RAD51
foci, at least 100 cells from each of three independent experiments were
visually scored for each condition. Cells with five or more RAD51 foci
were scored as positive.
Irradiation
Irradiations were performed using a Philips RT250 (Kimtron
Medical) at a dose rate of ~2 Gy/min in the University of Michigan
Comprehensive Cancer Center Experimental Irradiation Core.
Dosimetry was performed using an ionization chamber connected
to an electrometer system that is directly traceable to a National
Institute of Standards and Technology calibration. For tumor
irradiation, animals were anesthetized with isoflurane and positioned
such that the apex of each flank tumor was at the center of a 2.4-cm
aperture in the secondary collimator, with the rest of the mouse
shielded from radiation.
Tumor Growth Studies
Animals were handled in accordance with protocols approved by
the University of Michigan Committee for Use and Care of Animals.
Patient-derived xenografts were provided by Dr. Diane Simeone
(University of Michigan). Single-cell suspensions of patient-derived
xenografts were handled as described previously [36]. Five million
tumor cells were suspended in a 1:1 mixture of 10% FBS-DMEM/
Matrigel (BD Biosciences) and injected subcutaneously, bilaterally
into the flanks of 3- to 5-week-old female athymic nude mice
(Harlan). Treatment was initiated when the average tumor volume
(TV) reached 100 mm3 and consisted of gemcitabine (60 mg/kg;
days 0, 7), AZD1775 (30 mg/kg; QD; 2 h and 24 h postgemcitabine
and 1 h pre-radiation; days 0, 1 and 7, 8), and radiation (1.8 Gy/
fraction; days 0 to 4 and 7 to 11). Gemcitabine was administered via
intraperitoneal injection, and AZD1775 was administered via oral
gavage. Tumor size was measured two times per week. TV was
calculated according to the following equation: TV = π/6 (ab2),
where a and b are the longer and shorter dimensions of the tumor,
respectively. Measurements were made until day 50 or until the TV
increased by approximately a factor of 5.Statistics
Statistically significant differences for the clonogenic survival, flow
cytometry, and immunofluorescence assays were determined by
one-way ANOVA with the Tukey postcomparison test in GraphPad
PRISM version 5 (GraphPad software). For tumor growth experiments,
the time required for TVdoublingwas determined for each xenograft by
identifying the earliest day onwhich it was at least twice as large as on the
first day of treatment. The Kaplan-Meier method was used to analyze
the doubling times. Log-rank test (PROC LIFETEST in SAS) was used
to compare the doubling times between any two treatment groups. In
addition, the Bayesian hierarchical changepoint model [37] was used to
compare tumor regression rates, regression periods, and regrowth rates
between any two treatment groups.
Results
To investigate whether inhibition of the WEE1 kinase is an effective
strategy for sensitization of pancreatic cancers to chemoradiation, we
began by assessing radiation survival in a panel of pancreatic cancer
cell lines. MiaPaCa-2, Panc-1, and Capan-1 pancreatic cancer cells
were treated with minimally toxic concentrations of gemcitabine and
the WEE1 inhibitor AZD1775, followed by radiation (Figure 1A).
AZD1775 produced significant sensitization to gemcitabine-
radiation as evidenced by radiation enhancement ratios of 2.1 ± 0.2 and
1.5 ± 0.2 in MiaPaCa-2 and Panc-1 cells, respectively (Figure 1, B
and C; Suppl. Table 1). In contrast, Capan-1 cells were sensitized to
neither radiation nor gemcitabine-radiation by AZD1775, despite
being radiosensitized by gemcitabine (Figure 1D). These findings
suggest that pancreatic cancers may be differentially sensitized by
WEE1 inhibition and provide a rationale for investigation of the
mechanisms of sensitization to chemoradiation byWEE1 inhibition.
One possible explanation for differences in the ability of AZD1775
to sensitize different cells to chemoradiation is that AZD1775 does not
inhibit WEE1 effectively in all cell lines. As the primary activity of
WEE1 is phosphorylation of CDK1, which is associatedwith inhibition
of CDK1 activity and initiation of the G2 checkpoint [9], we analyzed
pCDK1 (Y15) protein levels by immunoblotting to verify WEE1
inhibition (Figure 2, A and B, Suppl. Figure 1). Although AZD1775
inhibited WEE1-mediated CDK1 phosphorylation in all three cell
lines, we found that higher concentrations of AZD1775 were required
to achieve similar inhibition of pCDK1 protein levels in MiaPaCa-2
and Panc-1 relative to Capan-1 cells. This result suggests that Capan-1
cells are not resistant to AZD1775-mediated radiosensitization as a
result of persistent WEE1 kinase activity.
As radiosensitization by AZD1775 has previously been attributed
to abrogation of the G2 checkpoint [15,20,22], we next evaluated the
ability of AZD1775 to inhibit radiation-induced G2 arrest in both
MiaPaCa-2 and Capan-1 cells. Flow cytometric analysis of the mitotic
marker pHistone H3 confirmed that AZD1775 abrogated the G2
checkpoint not only in cells sensitized to gemcitabine-radiation by
WEE1 inhibition (MiaPaCa-2; Figure 2C; Suppl. Figure 2) but also
in Capan-1 cells, which were not radiosensitized by AZD1775
(Figure 2D; Suppl. Figure 3). This finding suggests that AZD1775-
mediated G2 checkpoint abrogation is not sufficient for sensitization
to gemcitabine-radiation.
To begin to determine whether sensitization to chemoradiation by
AZD1775 is associated with inhibition of DNA DSB repair, we
assessed the resolution of γH2AX over time following radiation. In
MiaPaCa-2 cells, treatment with radiation or gemcitabine-radiation
caused a robust induction of γH2AX by 2 hours that was resolved to
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Figure 1. Sensitization to gemcitabine-radiation by AZD1775 in pancreatic cancer cells. Pancreatic cancer cells were treated with radiation
(RT) and equitoxic concentrations of gemcitabine (MiaPaCa-2, 100 nM; Panc-1, 50 nM; Capan-1, 50 nM) and/or AZD1775 (MiaPaCa-2 and
Panc-1, 200 nM; Capan-1, 50 nM) as illustrated (A). Radiation survival was assessed by clonogenic survival assay 24 hours post-RT in
MiaPaCa-2 (B), Panc-1 (C), and Capan-1 (D) cells. Plots are from single representative experiments. Radiation enhancement ratios (RERs;
inset) are the mean RER ± standard error of four to five independent experiments with statistical significance indicated versus GemRT*
(P b .05). Additional cytotoxicity data are shown in Suppl. Table 1.
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AZD1775 significantly delayed the resolution of γH2AX evidenced
by the significantly higher levels of γH2AX 24 hours postradiation
relative to either radiation or gemcitabine-radiation, consistent with
the presence of unrepaired DNA DSBs (Figure 3A, Suppl. Figure 4).
In contrast, Capan-1 cells treated with radiation or gemcitabine-
radiation exhibited a smaller initial induction of γH2AX relative to
MiaPaCa-2 cells, which persisted through the time course of the
experiment and is consistent with the intrinsic repair deficiency in
Capan-1 cells (Figure 3B). Importantly, AZD1775 did not further
delay the resolution of γH2AX in response to either radiation or
gemcitabine-radiation in these cells. The prolonged γH2AX DNA
damage response observed in MiaPaCa-2 cells treated with AZD1775
was also accompanied by an AZD1775-induced increase is pCHK1
(S345), another marker for sustained DNA damage that has
previously been associated with sensitization by CHK1 inhibition
(Figure 2A, Suppl. Figure 1B) [38,39]. In contrast, AZD1775 did not
increase pCHK1 (S345) levels in irradiated Capan-1 cells, although
AZD1775 alone induced CHK1 phosphorylation (Figure 2B). Taken
together, these findings are consistent with the differential effects of
AZD1775 on radiation survival in MiaPaCa-2 and Capan-1 cells and
suggest that inhibition of DNADSB repair is an important mechanism.
We and others have previously shown that WEE1 inhibition by
AZD1775 also inhibits HR [11,12]. Given the finding that
HR-proficient pancreatic cancer cells (MiaPaCa-2 and Panc-1) weresensitized to chemoradiation by WEE1 kinase inhibition whereas
BRCA2 mutant pancreatic cancer cells deficient in HR (Capan-1)
were not, we hypothesized that inhibition of HR may contribute to
AZD1775-mediated sensitization to chemoradiation. To test this
hypothesis, we assessed the ability of AZD1775 to sensitize an
isogenic pair of cell lines differing only in their BRCA2 status
(wild-type versus null; Suppl. Figure 5) to gemcitabine-radiation.
Radiation survival was assessed in BRCA2 wild-type and null DLD1
cells treated with equitoxic concentrations of gemcitabine and
AZD1775, as described in Figure 1. We found that BRCA2
wild-type cells were significantly sensitized to gemcitabine-radiation
by AZD1775 (Figure 4A, Suppl. Table 2). In contrast, although
BRCA2 null cells were intrinsically more radiosensitive than BRCA2
wild-type cells (Figure 4B, Suppl. Table 2), they were not further
sensitized to gemcitabine-radiation by AZD1775. The ability of HR
inhibition to sensitize to gemcitabine-radiation is further supported
by the finding that RAD51 depletion by siRNA also sensitized
MiaPaCa-2 cells to gemcitabine-radiation (Suppl. Figure 6).
As data fromprevious studies suggested that AZD1775-mediatedG2
checkpoint abrogation is the primary mechanism of radiosensitization
by WEE1 inhibition [15,20,22], we next assessed the ability of
AZD1775 to abrogate theG2 checkpoint in either BRCA2wild-type or
null cells treated with gemcitabine-radiation. Consistent with these
studies, we found that AZD1775 caused significant G2 checkpoint
abrogation in response to gemcitabine-radiation in BRCA2 wild-type
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Figure 2. The effects of AZD1775 and gemcitabine-radiation on DNA damage checkpoint signaling and abrogation of the G2 checkpoint.
MiaPaCa-2 (A, C) and Capan-1 (B, D) cells were treated with gemcitabine, AZD1775, and radiation as described in Figure 1. Six hours
post-RT (6 Gy), cells were harvested for immunoblotting (A, B). Images are from single representative experiments. Quantitation of
immunoblots is shown in Suppl. Figure 1. Alternatively, samples were analyzed for pHistone H3 (Ser10) and DNA content by flow
cytometry (C, D). Data are the mean percentage ± standard error of pHistone H3–positive mitotic cells from three independent
experiments. Statistical significance is indicated versus RT* or GemRT† (P b .05).
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G2 checkpoint in the BRCA2 null cells, which were not sensitized to
chemoradiation by AZD1775 (Figure 4D). Thus, although 200 nM
AZD1775 was sufficient to inhibit WEE1 in the BRCA2 null DLD10 4 8 12 16 20 24
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Figure 4. Sensitization to gemcitabine-radiation by AZD1775 involves inhibition of HR. Radiation survival was assessed in BRCA2
wild-type and BRCA2 null isogenic DLD1 cells treated with equitoxic concentrations of gemcitabine (BRCA2 wild-type, 100 nM; BRCA2
null, 50 nM) and AZD1775 (200 nM) as illustrated in Figure 1. Plots are from single representative experiments (A, B). RERs (inset) are the
mean RER ± standard error of three to four independent experiments with statistical significance indicated versus control* (P b .05).
Additional cytotoxicity data are given in Suppl. Table 2. BRCA2 isogenic DLD1 cells were analyzed for pHistone H3 (Ser10) and DNA
content 6 hours post-RT (C, D). Data presented are themean percentage ± standard error of pHistone H3–positive mitotic cells from three
independent experiments with statistical significance indicated versus RT* or GemRT† (P b .05). RAD51 foci were analyzed at 24 hours
post-RT (6 Gy). Cells with five or more foci were scored as RAD51 positive (E). Data presented are the mean percentage ± standard
deviation of RAD51-positive cells from two independent experiments. Images of RAD51 foci are presented in Suppl. Figure 7.
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formation. Consistent with the HR-proficient and -deficient status
of these cells, BRCA2 wild-type cells formed RAD51 foci in response
to gemcitabine-radiation, whereas BRCA2 null cells did not (Suppl.
Figure 7). Furthermore, AZD1775 inhibited RAD51 focus forma-
tion by gemcitabine-radiation in the BRCA2 wild-type cells
(Figure 4E). Taken together, these results demonstrate that
AZD1775 preferentially sensitizes BRCA2 wild-type, HR-proficient
cells to gemcitabine chemoradiation and suggest that inhibition of
HR, in contrast to G2 checkpoint abrogation, is an important
mechanism of action for sensitization to chemoradiation.
Having demonstrated that AZD1775 sensitizes HR-proficient
pancreatic cancer cells to gemcitabine chemoradiation in vitro, we
next assessed the ability of AZD1775 to sensitize a patient-derived
pancreatic tumor xenograft, designated 08-444T, to chemoradiation
in vivo. Tumor-bearing mice were treated for two cycles with
gemcitabine, AZD1775, and fractionated radiation (Figure 5A). In the
absence of radiation, treatment with gemcitabine and/or AZD1775 had
minimal effect on tumor growth (Figure 5B). In contrast, treatment with
radiation, alone or in combination with gemcitabine and/or AZD1775,
significantly inhibited tumor growth rates. AZD1775 did not
significantly sensitize tumors to radiation alone, a result consistent
with the modest sensitization by AZD1775 to radiation alone observed
in vitro (Figure 1). AZD1775 did, however, sensitize patient-derived
pancreatic tumor xenografts to gemcitabine-radiation as evidenced by
significantly longer times required for tumor volume doubling in
response to AZD1775 in combination with gemcitabine-radiation (34A) Treatment schedule 
2 cycles
AZD1775
RT RT RT RT
Gem
AZD1775
RT
IB/IF
Day 1 Day 2 Day 4Day 3Day 0
Control
Gem 
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GemAZD1775RT                          
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16 (9,18) 
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17 (8, 25) 
21.5 (18, 23)                
21 (16,26)                    
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*Growth rates were significantly reduced in all RT
groups vs. control. GemAZD1775RT showed a
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Figure 5. Sensitization of patient-derived pancreatic tumor xenografts
(A; IB, immunblotting; IF, immunofluorescence) Athymic nude mice b
designated 08-444T, were randomized to the indicated treatment gro
AZD1775 (50 mg/kg QD days 0 to 1 and 7 to 8) and RT (1.8 Gy/frac
normalized to the tumor volume on the first day of treatment (day 0) ±
doubling with lower and upper limits in parentheses (C). Data are fr
indicated versus control*, RT† and GemRT‡ (P b .05).days) compared with gemcitabine-radiation (21.5 days) (Figure 5C).
Treatment with the combination of AZD1775 and gemcitabine-
radiation was tolerable as evidenced by 10% or less weight loss during
treatment with no other obvious adverse events (data not shown). Taken
together, these results demonstrate that AZD1775 is an effective strategy
for sensitizing patient-derived pancreatic tumor xenografts to gemcita-
bine chemoradiation.
Finally, to better understand the mechanism(s) by which AZD1775-
mediated WEE1 inhibition sensitizes tumors to gemcitabine-
radiation in vivo, we assessed the DNA damage response in tumors
from animals bearing patient-derived pancreatic tumor xenografts
that were treated acutely with gemcitabine, radiation, and/or
AZD1775 (Figure 5A). pCDK1 (Y15) protein levels were reduced
in response to AZD1775 alone or in combination with gemcitabine-
radiation, consistent with inhibition of WEE1 kinase activity
(Figure 6A; Suppl. Figure 8). Furthermore, although pCHK1
(S345), a marker of DNA damage [38] and replication stress [40],
was elevated in response to either gemcitabine or AZD1775 alone,
the greatest effect on pCHK1 (S345) was seen in response to the
triple combination of gemcitabine, radiation, andAZD1775. Finally, to
determine whether inhibition of HR is a mechanism of AZD1775-
mediated sensitization to chemoradiation in vivo, RAD51 foci were
measured in tumor xenografts from mice treated with radiation,
gemcitabine, and/or AZD1775. Treatment with gemcitabine or
gemcitabine-radiation resulted in the most RAD51 focus formation
with 6.0% or 8.6% of cells staining positive for RAD51 foci,
respectively (Figure 6, B and C; Suppl. Figure 9). Importantly,Days post-treatment initiation
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Figure 6. Sensitization of patient-derived tumor xenografts to gemcitabine-radiation by AZD1775 involves inhibition of HR. Athymic nude
mice bearing 08-444T subcutaneous, patient-derived pancreatic tumor xenografts were treated as described in Figure 5, except that, on
day 1 (2 hours post-RT), tumors were harvested for immunoblotting (A) and immunofluorescence (B, C). Immunoblot images are from a
single representative experiment. Additional independent experiments are shown in Suppl. Figure 8. Tumors were stained with
anti-RAD51 antibody (green) and DAPI (blue). Cells with five or more RAD51 foci were scored as positive. Data are the mean ± standard
error of RAD51 positive cells from three to four tumors per treatment condition. Statistical significance versus GemRT* is indicated (P b .05).
Additional RAD51 images are provided in Suppl. Figure 9.
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induced by gemcitabine-radiation under conditions which did not alter
cellular RAD51 protein levels (Figure 6A). These results support the
hypothesis that inhibition of HR repair is a significant mechanism of
sensitization to chemoradiation by WEE1 inhibitors in patient-derived
pancreatic tumors.
Discussion
In this study, we found that WEE1 inhibition by AZD1775 is an
effective strategy for sensitizing HR-competent pancreatic cancers to
gemcitabine chemoradiation. Our data show that although WEE1
inhibition is associated with abrogation of the G2 checkpoint, this
mechanism may not be sufficient for sensitization. Rather, our
findings support the hypothesis that sensitization to chemoradiation
by WEE1 inhibition results from inhibition of HR, leading to
persistent radiation-induced DNA damage. Taken together, these
data suggest that inhibition of HR repair is an important mechanism
of action for the therapeutic activity of WEE1 inhibitors and,
furthermore, that the combined treatment of a WEE1 inhibitor with
chemoradiation may be most effective in pancreatic cancers withoutunderlying HR defects. Given that 5% of pancreatic cancers harbor
BRCA1/2 mutations [41], the findings of this study have important
clinical implications.
The finding that AZD1775-mediated WEE1 inhibition causes
impaired HR is consistent with previous studies from our group and
others [12,42]. CDK1 activation in response to WEE1 inhibition
represents a plausible mechanism of HR regulation by WEE1 which
is further suggested by the finding that several different agents which
result in CDK1 activation, including PP2A and CHK1 inhibitors,
also inhibit HR [39,43,44]. CDK1 and CDK2 play a critical role in
the cell cycle–dependent regulation of HR, limiting HR activity only
to S or G2 phases of the cell cycle. The role of CDK1/2 in HR is
complex because it both positively and negatively regulates HR. For
example, CDK1/2-mediated phosphorylation of RPA, CtIP, and
NBS1 positively regulates HR [45]. In contrast, CDK1-mediated
phosphorylation of BRCA2 (S3291) negatively regulates HR by
disrupting the interaction between BRCA2 and RAD51 [46].
AZD1775 has previously been shown to increase phosphorylation
of BRCA2 (S3291), suggesting that this is a mechanism for inhibition
of HR activity by WEE1 inhibitor [12]. Here we demonstrate for the
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chemoradiation by WEE1 inhibition.
Although we have focused on understanding the therapeutic
significance of the ability of WEE1 to regulate both the G2 checkpoint
and HR in response to chemoradiation-induced DNA damage, studies
suggest that WEE1 also regulates DNA replication in unstressed cells.
According to this model, the hyperactivation of CDK1 caused by
WEE1 inhibition leads to futile cycles of increased replication origin
firing, nucleotide depletion, and decreased replication fork progression
[10,18]. This replication stress activates the MUS81-EME1 endonu-
clease which catalyzes DNA DSBs at the sites of aberrant replication
structures [18,47]. Although the early increase in γH2AX levels in
MiaPaCa-2 cells treated with AZD1775 alone is consistent with this
model (Figure 3C; t = 0 hour), the relative contribution of replication
stress to radiosensitization by WEE1 inhibition is currently unknown.
Although our study suggests that sensitization to chemoradiation by
WEE1 inhibition occurs preferentially in HR-proficient cells, the
single-agent activity ofWEE1 inhibition is greatest inHR-deficient cells
[48], a finding that is supported by the activity of AZD1775 in patients
carrying BRCA2 mutations [49]. These seemingly contradictory
findings suggest that different mechanisms are responsible for the
single- versus combined-agent activity of WEE1 inhibitors. It is
plausible that in the absence of exogenous DNA damage, DNA
replication–associatedmechanisms have a greater contribution, whereas
in the presence of exogenous DNA damage, DNA damage response–
associated mechanisms (cell cycle checkpoints and DSB repair) are of
increased importance. Furthermore, in combinatorial approaches, the
key mechanisms contributing to cytotoxicity are likely dependent on
the type of agent being combined with the WEE1 inhibitor. For
example, in combination with chemotherapies such as antimetabolites,
which function primarily via perturbing DNA replication, the ability of
WEE1 to regulate DNA replication may be of increased importance. In
contrast, for agents such as ionizing radiation, which directly induce
DNADSBs, the ability of WEE1 to regulate cell cycle checkpoints and
DNA DSB repair is likely of greater relative importance. In addition, it
is likely that these pathways exhibit differential concentration
responsiveness to WEE1 inhibition which may also influence their
contributions to the single- versus combined-agent activity of WEE1
inhibitors. Future studies will be required to define the relative
contributions of cell cycle checkpoints, DNA DSB repair, and DNA
replication to the therapeutic activity of WEE1 inhibitors alone or in
combination with other agents.
There is substantial evidence to support the hypothesis that tumor
cells expressing mutant P53 are more sensitive than cells expressing
wild-type P53 to the therapeutic effects of checkpoint inhibitors such
as AZD1775 on radiosensitivity [16,50]. This selectivity is generally
attributed to the combined effects of G1 checkpoint loss in P53
mutant cancer cells and G2 checkpoint loss following WEE1 or
CHK1 inhibition, which together promote cellular proliferation
despite the presence of unrepaired DNA damage. The ability of
AZD1775 to inhibit HR, however, suggests an alternative model.
Because P53 mutant cancer cells treated with ionizing radiation do
not arrest in G1, where NHEJ is the dominant DNA DSB repair
pathway, these cells likely have an increased dependency on other
DNA DSB repair pathways, such as HR [51]. Thus, the relatively
selective radiosensitization by WEE1 inhibitors such as AZD1775 in
cancer cells which lack functional p53 may result from a shift in
dependence from NHEJ to HR for repair of ionizing radiation-
induced DNA DSBs combined with inhibition of HR activity.The findings of this study demonstrating the efficacy of WEE1
inhibition for sensitizing pancreatic cancers to chemoradiation
represent a promising strategy for improving therapy in locally
advanced pancreatic cancer patients. Furthermore, these findings
suggest that patients selected on the basis of having an intact HR
repair pathway may benefit most from this therapeutic strategy. The
results of this study are the foundation of our current clinical trial
combining AZD1775 with gemcitabine-radiation in locally advanced
pancreatic cancer patients (NCT02037230) and provide a rationale
for patient selection on the basis of HR status for future clinical trials.
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